suppressor of cytokine signaling 5 pseudogene 5Genealiases: []
Q-omics provides the consensus-scored SOCS5P5 profile across patient tissues and cancer cell-line models. SOCS5P5 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SOCS5P5 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, SOCS5P5 RNA expression shows 12,886 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, BRCA, and THYM as cancer lineages where SOCS5P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOCS5P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOCS5P5 survival associations across molecular data types. SOCS5P5 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOCS5P5 RNA expression–survival associations across cancer types. High SOCS5P5 expression shows unfavorable associations in LIHC, STAD, ACC, COAD and KICH, but favorable associations in BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SOCS5P5 RNA expression.
This table summarizes SOCS5P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SOCS5P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOCS5P5 shows lower tumor expression in KIRC and higher tumor expression in BRCA and LIHC. The BRCA box plot shows higher SOCS5P5 RNA expression in tumor versus normal tissue (log2 FC = +0.004, t-test p = .019).
This table shows molecular features associated with SOCS5P5 in patient tissues and cancer cell lines. In patient samples, SOCS5P5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
